Tata Medical & Diagnostics on Wednesday mentioned it has indigenously developed a fast-testing answer for COVID-19 to considerably increase India’s testing capability amid the Omicron variant risk.
The answer, Tata MD CHECK Specific RT-PCR, could be utilized in a number of areas the place fast, excessive quantity, and dependable testing is required, reminiscent of airports and occasions, the corporate claimed.
With research in India pointing to a potential surge in circumstances in February subsequent 12 months, there may be anticipated to be a multifold enhance in demand for RT-PCR COVID exams which might be economical and provides quick outcomes, it added.
To satisfy this problem, Tata Medical & Diagnostics (Tata MD) has indigenously developed the COVID testing options that may considerably increase India’s COVID testing capability, the corporate mentioned.
Its options embody ‘Tata MD CHECK XF’, a equipment that has a processing time of 1 hour and might course of 30 samples per batch per machine. It’s authorised by ICMR with over 95 per cent sensitivity and 100 per cent specificity.
The opposite one is the ‘Tata MD CHECK RT-PCR Quick 3Gene’ equipment that makes use of a quick amplification protocol, with a processing time of 90 minutes and might course of 90 samples per batch per machine. It’s authorised by ICMR with 100 per cent sensitivity and 100 per cent specificity, the corporate mentioned.
Tata Medical & Diagnostics CEO Girish Krishnamurthy mentioned the corporate was striving to indigenously develop revolutionary medical applied sciences and dealing on a number of new applied sciences for COVID-19 testing.
“These categorical testing options could be utilized in a number of areas the place fast, excessive quantity, and dependable testing is required reminiscent of airports and occasions,” he added.
The corporate mentioned its new Tata MD CHECK Specific PCR testing answer has been in use on the Kempegowda Worldwide Airport, Bengaluru, since early this month and has confirmed to ship speedy and reliable leads to a real-world surroundings with a excessive quantity of exams.
“It has proved instrumental in serving to to deal with the push of fliers from ‘excessive threat’ international locations required to bear obligatory RT-PCR testing,” the corporate mentioned.
Final 12 months in November, the corporate had launched its COVID testing equipment, ‘TataMD CHECK’, developed in partnership with CSIR-IGIB (Council of Scientific and Industrial Analysis-Institute of Genomics and Integrative Biology). It has been authorised by the Indian Council of Medical Analysis and Drug Controller Common of India (DCGI).